A Quantum Key Distribution Network Through Single Mode Optical Fiber

Quantum key distribution (QKD) has been developed within the last decade that is provably secure against arbitrary computing power, and even against quantum computer attacks. Now there is a strong need of research to exploit this technology in the existing communication networks. In this paper we have presented various experimental results pertaining to QKD like Raw key rate and Quantum bit error rate (QBER). We found these results over 25 km single mode optical fiber. The experimental setup implemented the enhanced version of BB84 QKD protocol. Based upon the results obtained, we have presented a network design which can be implemented for the realization of large scale QKD networks. Furthermore, several new ideas are presented and discussed to integrate the QKD technique in the classical communication networks.Comment: This paper has been submitted to the 2006 International Symposium on Collaborative Technologies and Systems (CTS 2006)May 14-17, 2006, Las Vegas, Nevada, US

Bioinformatic analysis reveals the expression of unique transcriptomic signatures in Zika virus infected human neural stem cells

BACKGROUND: The single-stranded RNA Flavivirus, Zika virus (ZIKV), has recently re-emerged and spread rapidly across the western hemisphere’s equatorial countries, primarily through Aedes mosquito transmission. While symptoms in adult infections appear to be self-limiting and mild, severe birth defects, such as microcephaly, have been linked to infection during early pregnancy. Recently, Tang et al. (Cell Stem Cell 2016, doi: 10.1016/j.stem.2016.02.016) demonstrated that ZIKV efficiently infects induced pluripotent stem cell (iPSC) derived human neural progenitor cells (hNPCs), resulting in cell cycle abnormalities and apoptosis. Consequently, hNPCs are a suggested ZIKV target. METHODS: We analyzed the transcriptomic sequencing (RNA-seq) data (GEO: GSE78711) of ZIKV (Strain: MR766) infected hNPCs. For comparison to the ZIKV-infected hNPCs, the expression data from hNPCs infected with human cytomegalovirus (CMV) (Strain: AD169) was used (GEO: GSE35295). Utilizing a combination of Gene Ontology, database of human diseases, and pathway analysis, we generated a putative systemic model of infection supported by known molecular pathways of other highly related viruses. RESULTS: We analyzed RNA-sequencing data for transcript expression alterations in ZIKV-infected hNPCs, and then compared them to expression patterns of iPSC-derived hNPCs infected with CMV, a virus that can also induce severe congenital neurological defects in developing fetuses. We demonstrate for the first time that many of cellular pathways correlate with clinical pathologies following ZIKV infection such as microcephaly, congenital nervous system disorders and epilepsy. Furthermore, ZIKV activates several inflammatory signals within infected hNPCs that are implicated in innate and acquired immune responses, while CMV-infected hNPCs showed limited representation of these pathways. Moreover, several genes related to pathogen responses are significantly upregulated upon ZIKV infection, but not perturbed in CMV-infected hNPCs. CONCLUSION: The presented study is the first to report enrichment of numerous pro-inflammatory pathways in ZIKV-infected hNPCs, indicating that hNPCs are capable of signaling through canonical pro-inflammatory pathways following viral infection. By defining gene expression profiles, new factors in the pathogenesis of ZIKV were identified which could help develop new therapeutic strategies

Nastaliq Optical Character Recognition

Nastaliq is a calligraphic, beautiful and more aesthetic style of writing Urdu, the national language of Pakistan, also used to read and write in India and other countries of the region. OCRs developed for many world languages are already under efficient use but none exist for Nastaliq - a calligraphic adaptation of the Arabic scrip which is inherently cursive in nature. In Nastaliq, word and character overlapping makes optical recognition more complex. This paper presents the ongoing research on Nastaliq Optical Character Recognition (NOCR). In this research, we have proposed a novel segmentation-free technique for the design and implementation of a Nastaliq OCR based on cross-correlation. Copyright 2008 ACM

Implementation Challenges for Nastaliq Character Recognition

Character recognition in cursive scripts or handwritten Latin script has attracted researchers’ attention recently and some research has been done in this area. Optical character recognition is the translation of optically-scanned bitmaps of printed or written text into digitally editable data files. OCRs developed for many world languages are already in use but none exists for Urdu Nastaliq – a calligraphic adaptation of the Arabic script, just as Jawi is for Malay. Urdu Nastaliq has 39 characters against Arabic 28. Each character then has 2-4 different shapes according to its position in the word: initial, medial, final and isolated. In Nastaliq, inter-word and intra-word overlapping makes optical recognition more complex. Character recognition of the Latin script is relatively easier. This paper reports research on Urdu Nastaliq OCR, discusses challenges and suggest a new solution for its implementation

Thigh-length compression stockings and DVT after stroke

Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research